Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: A population-based case control study

Ylenia Ingrasciotta, Janet Sultana, Francesco Giorgianni, Andrea Fontana, Antonio Santangelo, Daniele Ugo Tari, Domenico Santoro, Vincenzo Arcoraci, Margherita Perrotta, Luisa Ibanez, Gianluca Trifiro

Research output: Contribution to journalArticle

Abstract

Background: Non-steroidal anti-inflammatory agents (NSAIDs) are known to be associated with renal damage. No clear evidence exists regarding differential risk of chronic kidney disease (CKD), specifically, across various NSAIDs. Aim: The aim of this population-based case-control study was to evaluate the association between use of individual NSAIDs and risk of CKD in a general population of Southern Italy. Methods: A nested case-control study was carried out using the general practice Arianna database, identifying incident CKD patients as cases and matched controls from 2006 to 2011. The date of first CKD diagnosis was defined as the index date (ID). Conditional logistic regressions were performed to estimate the risk of CKD associated with NSAIDs by class and individual drugs as compared to non-use during different time windows (within one year, six or three months prior to ID), with the latter being defined as current users. Among current users, the effect of cumulative exposure to these drugs was evaluated. Results: Overall, 1,989 CKD cases and 7,906 matched controls were identified. A statistically significant increase in the risk of CKD was found for current users of oxicams (adjusted OR: 1.68; 95% CI: 1.15-2.44) and concerning individual compounds, for ketorolac (adj. OR: 2.54; 95% CI: 1.45-4.44), meloxicam (adj. OR: 1.98; 95% CI: 1.01-3.87) and piroxicam (adj. OR: 1.95; 95% CI: 1.19-3.21). Conclusions: The risk of CKD varies across individual NSAIDs. Increased risk has been found for ketorolac, which may precipitate subclinical CKD through acute renal damage, and long-term exposure to oxicams, especially meloxicam and piroxicam.

Original languageEnglish
Article numbere0122899
JournalPLoS One
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 16 2015

Fingerprint

nonsteroidal anti-inflammatory agents
kidney diseases
case-control studies
Chronic Renal Insufficiency
Case-Control Studies
Anti-Inflammatory Agents
Non-Steroidal Anti-Inflammatory Agents
meloxicam
Pharmaceutical Preparations
Population
Ketorolac
Piroxicam
kidneys
cumulative exposure
Kidney
drugs
risk estimate
disease diagnosis
chronic exposure
General Practice

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ingrasciotta, Y., Sultana, J., Giorgianni, F., Fontana, A., Santangelo, A., Tari, D. U., ... Trifiro, G. (2015). Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: A population-based case control study. PLoS One, 10(4), [e0122899]. https://doi.org/10.1371/journal.pone.0122899

Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease : A population-based case control study. / Ingrasciotta, Ylenia; Sultana, Janet; Giorgianni, Francesco; Fontana, Andrea; Santangelo, Antonio; Tari, Daniele Ugo; Santoro, Domenico; Arcoraci, Vincenzo; Perrotta, Margherita; Ibanez, Luisa; Trifiro, Gianluca.

In: PLoS One, Vol. 10, No. 4, e0122899, 16.04.2015.

Research output: Contribution to journalArticle

Ingrasciotta, Y, Sultana, J, Giorgianni, F, Fontana, A, Santangelo, A, Tari, DU, Santoro, D, Arcoraci, V, Perrotta, M, Ibanez, L & Trifiro, G 2015, 'Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: A population-based case control study', PLoS One, vol. 10, no. 4, e0122899. https://doi.org/10.1371/journal.pone.0122899
Ingrasciotta, Ylenia ; Sultana, Janet ; Giorgianni, Francesco ; Fontana, Andrea ; Santangelo, Antonio ; Tari, Daniele Ugo ; Santoro, Domenico ; Arcoraci, Vincenzo ; Perrotta, Margherita ; Ibanez, Luisa ; Trifiro, Gianluca. / Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease : A population-based case control study. In: PLoS One. 2015 ; Vol. 10, No. 4.
@article{7feb2efea82b41a28d85603451959727,
title = "Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: A population-based case control study",
abstract = "Background: Non-steroidal anti-inflammatory agents (NSAIDs) are known to be associated with renal damage. No clear evidence exists regarding differential risk of chronic kidney disease (CKD), specifically, across various NSAIDs. Aim: The aim of this population-based case-control study was to evaluate the association between use of individual NSAIDs and risk of CKD in a general population of Southern Italy. Methods: A nested case-control study was carried out using the general practice Arianna database, identifying incident CKD patients as cases and matched controls from 2006 to 2011. The date of first CKD diagnosis was defined as the index date (ID). Conditional logistic regressions were performed to estimate the risk of CKD associated with NSAIDs by class and individual drugs as compared to non-use during different time windows (within one year, six or three months prior to ID), with the latter being defined as current users. Among current users, the effect of cumulative exposure to these drugs was evaluated. Results: Overall, 1,989 CKD cases and 7,906 matched controls were identified. A statistically significant increase in the risk of CKD was found for current users of oxicams (adjusted OR: 1.68; 95{\%} CI: 1.15-2.44) and concerning individual compounds, for ketorolac (adj. OR: 2.54; 95{\%} CI: 1.45-4.44), meloxicam (adj. OR: 1.98; 95{\%} CI: 1.01-3.87) and piroxicam (adj. OR: 1.95; 95{\%} CI: 1.19-3.21). Conclusions: The risk of CKD varies across individual NSAIDs. Increased risk has been found for ketorolac, which may precipitate subclinical CKD through acute renal damage, and long-term exposure to oxicams, especially meloxicam and piroxicam.",
author = "Ylenia Ingrasciotta and Janet Sultana and Francesco Giorgianni and Andrea Fontana and Antonio Santangelo and Tari, {Daniele Ugo} and Domenico Santoro and Vincenzo Arcoraci and Margherita Perrotta and Luisa Ibanez and Gianluca Trifiro",
year = "2015",
month = "4",
day = "16",
doi = "10.1371/journal.pone.0122899",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease

T2 - A population-based case control study

AU - Ingrasciotta, Ylenia

AU - Sultana, Janet

AU - Giorgianni, Francesco

AU - Fontana, Andrea

AU - Santangelo, Antonio

AU - Tari, Daniele Ugo

AU - Santoro, Domenico

AU - Arcoraci, Vincenzo

AU - Perrotta, Margherita

AU - Ibanez, Luisa

AU - Trifiro, Gianluca

PY - 2015/4/16

Y1 - 2015/4/16

N2 - Background: Non-steroidal anti-inflammatory agents (NSAIDs) are known to be associated with renal damage. No clear evidence exists regarding differential risk of chronic kidney disease (CKD), specifically, across various NSAIDs. Aim: The aim of this population-based case-control study was to evaluate the association between use of individual NSAIDs and risk of CKD in a general population of Southern Italy. Methods: A nested case-control study was carried out using the general practice Arianna database, identifying incident CKD patients as cases and matched controls from 2006 to 2011. The date of first CKD diagnosis was defined as the index date (ID). Conditional logistic regressions were performed to estimate the risk of CKD associated with NSAIDs by class and individual drugs as compared to non-use during different time windows (within one year, six or three months prior to ID), with the latter being defined as current users. Among current users, the effect of cumulative exposure to these drugs was evaluated. Results: Overall, 1,989 CKD cases and 7,906 matched controls were identified. A statistically significant increase in the risk of CKD was found for current users of oxicams (adjusted OR: 1.68; 95% CI: 1.15-2.44) and concerning individual compounds, for ketorolac (adj. OR: 2.54; 95% CI: 1.45-4.44), meloxicam (adj. OR: 1.98; 95% CI: 1.01-3.87) and piroxicam (adj. OR: 1.95; 95% CI: 1.19-3.21). Conclusions: The risk of CKD varies across individual NSAIDs. Increased risk has been found for ketorolac, which may precipitate subclinical CKD through acute renal damage, and long-term exposure to oxicams, especially meloxicam and piroxicam.

AB - Background: Non-steroidal anti-inflammatory agents (NSAIDs) are known to be associated with renal damage. No clear evidence exists regarding differential risk of chronic kidney disease (CKD), specifically, across various NSAIDs. Aim: The aim of this population-based case-control study was to evaluate the association between use of individual NSAIDs and risk of CKD in a general population of Southern Italy. Methods: A nested case-control study was carried out using the general practice Arianna database, identifying incident CKD patients as cases and matched controls from 2006 to 2011. The date of first CKD diagnosis was defined as the index date (ID). Conditional logistic regressions were performed to estimate the risk of CKD associated with NSAIDs by class and individual drugs as compared to non-use during different time windows (within one year, six or three months prior to ID), with the latter being defined as current users. Among current users, the effect of cumulative exposure to these drugs was evaluated. Results: Overall, 1,989 CKD cases and 7,906 matched controls were identified. A statistically significant increase in the risk of CKD was found for current users of oxicams (adjusted OR: 1.68; 95% CI: 1.15-2.44) and concerning individual compounds, for ketorolac (adj. OR: 2.54; 95% CI: 1.45-4.44), meloxicam (adj. OR: 1.98; 95% CI: 1.01-3.87) and piroxicam (adj. OR: 1.95; 95% CI: 1.19-3.21). Conclusions: The risk of CKD varies across individual NSAIDs. Increased risk has been found for ketorolac, which may precipitate subclinical CKD through acute renal damage, and long-term exposure to oxicams, especially meloxicam and piroxicam.

UR - http://www.scopus.com/inward/record.url?scp=84928480953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928480953&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0122899

DO - 10.1371/journal.pone.0122899

M3 - Article

AN - SCOPUS:84928480953

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0122899

ER -